Published in Healthcare Mergers, Acquisitions and Ventures Week, May 1st, 2004
AMDL's product revenues for the year ended December 31, 2003, totaled $360,000, a 101.2% increase compared to product revenues of $179,000 for the year ended December 31, 2002.
Net loss for fiscal 2003 was $2.9 million or ($0.23) per share compared to a net loss of $3.6 million, or ($0.42) per share, for the year ended December 31, 2002.
"The company's primary objective remains receiving U.S. Food and Drug Administration clearance to market its DR-70 test in the U.S. FDA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.